{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:16Z","timestamp":1792785016615,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novartis Farma S.p.A.","id":[{"id":"https:\/\/ror.org\/03fjwdh27","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.blre.2019.100594","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:46:55Z","timestamp":1565207215000},"page":"100594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Management of the aging beta-thalassemia transfusion-dependent population \u2013 The Italian experience"],"prefix":"10.1016","volume":"38","author":[{"given":"Valeria Maria","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.100594_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.100594_bb0010","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.blre.2019.100594_bb0015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3324\/haematol.2011.055962","article-title":"Beta-thalassemia: from genotype to phenotype","volume":"96","author":"Danjou","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0020","series-title":"Guidelines for the management of transfusion dependent thalassaemia (TDT)","author":"Trompeter","year":"2014"},{"key":"10.1016\/j.blre.2019.100594_bb0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0030","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0035","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/ajh.22102","article-title":"Changing patterns of splenectomy in transfusion-dependent thalassemia patients","volume":"86","author":"Piga","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0040","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.3109\/03630260903347336","article-title":"Update on survival in thalassemia major","volume":"33","author":"Telfer","year":"2009","journal-title":"Hemoglobin"},{"key":"10.1016\/j.blre.2019.100594_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1196\/annals.1345.006","article-title":"Survival and complications in thalassemia","volume":"1054","author":"Borgna-Pignatti","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/nyas.13041","article-title":"Management of beta-thalassemia-associated osteoporosis","volume":"1368","author":"Giusti","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/asheducation-2017.1.272","article-title":"Impact of bone disease and pain in thalassemia","volume":"2017","author":"Piga","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2019.100594_bb0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1365-2141.2003.04732.x","article-title":"Hepatocellular carcinoma in the thalassaemia syndromes","volume":"124","author":"Borgna-Pignatti","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/nyas.13005","article-title":"Malignancies and thalassemia: a review of the literature","volume":"1368","author":"Zanella","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0070","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bcmd.2015.08.004","article-title":"Klotho, a new marker for osteoporosis and muscle strength in \u03b2-thalassemia major","volume":"55","author":"Baldan","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0075","series-title":"Guidelines for the management of non transfusion dependent thalassaemia (ntdt)","author":"Taher","year":"2013"},{"key":"10.1016\/j.blre.2019.100594_bb0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/ijms19010182","article-title":"Non-transfusion-dependent thalassemia: an update on complications and management","volume":"19","author":"Sleiman","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0085","series-title":"Prevention of thalassaemias and other haemoglobin disorders","article-title":"2. Epidemiology of haemoglobinopathies","volume":"vol. 1","author":"Angastiniotis","year":"2013"},{"key":"10.1016\/j.blre.2019.100594_bb0090","series-title":"Ithanet","author":"The Ithanet Consortium","year":"2009"},{"key":"10.1016\/j.blre.2019.100594_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1749-6632.1990.tb24309.x","article-title":"Antenatal diagnosis of \u03b2-thalassemia in Sardinia","volume":"612","author":"Cao","year":"1990","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0100","first-page":"592","article-title":"Prevention of homozygous \u03b2-thalassemia by carrier screening and prenatal diagnosis in Sardinia","volume":"33","author":"Cao","year":"1981","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.blre.2019.100594_bb0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bcmd.2017.10.003","article-title":"Hematological phenotypes in children according to the \u03b1-globin genotypes","volume":"69","author":"Origa","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7020035","article-title":"From prenatal to preimplantation genetic diagnosis of \u03b2-thalassemia. Prevention model in 8748 cases: 40 years of single center experience","volume":"7","author":"Monni","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2019.100594_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"2","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.100594_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1749-6632.1998.tb10479.x","article-title":"Survival and disease complications in thalassemia major","volume":"850","author":"Borgna-Pignatti","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0125","author":"Societ\u00e0 Italiana Talassemie ed Emoglobinopatie (SITE)"},{"key":"10.1016\/j.blre.2019.100594_bb0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ajh.21398","article-title":"The influence of treatment in specialized centers on survival of patients with thalassemia major","volume":"84","author":"Forni","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0135","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","article-title":"How I manage medical complications of beta-thalassemia in adults","volume":"132","author":"Taher","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100594_bb0140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/03007995.2017.1326890","article-title":"Pattern of complications and burden of disease in patients affected by beta thalassemia major","volume":"33","author":"Bonifazi","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2019.100594_bb0145","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s002280000251","article-title":"Pharmacosurveillance and quality of care of thalassaemic patients. a large scale epidemiological survey","volume":"56","author":"Arboretti","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2019.100594_bb0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajh.25103","article-title":"The effect of iron chelation therapy on overall survival in sickle cell disease and beta-thalassemia: a systematic review","volume":"93","author":"Ballas","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0160","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.284.6322.1081","article-title":"Survival and desferrioxamine in thalassaemia major","volume":"284","author":"Modell","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.blre.2019.100594_bb0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2019.100594_bb0170","first-page":"817","article-title":"Long-term follow-up of skeletal dysplasia in thalassaemia major","volume":"11","author":"Naselli","year":"1998","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.blre.2019.100594_bb0175","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2019.100594_bb0180","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/er.2015-1105","article-title":"Bone disease in thalassemia: a molecular and clinical overview","volume":"37","author":"Wong","year":"2016","journal-title":"Endocr Rev"},{"key":"10.1016\/j.blre.2019.100594_bb0185","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2214\/ajr.156.3.1899759","article-title":"Deferoxamine-induced bone dysplasia in patients with thalassemia major","volume":"156","author":"Brill","year":"1991","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.blre.2019.100594_bb0190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3476(88)80375-5","article-title":"Deferoxamine-induced growth retardation in patients with thalassemia major","volume":"113","author":"De Virgiliis","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.blre.2019.100594_bb0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian society for thalassemia and Hemoglobinopathies","volume":"42","author":"Maggio","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0200","article-title":"Deferasirox: over a decade of experience in thalassemia","volume":"10","author":"Moukalled","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0205","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212502","article-title":"Advances in iron chelation therapy: transitioning to a new oral formulation","volume":"6","author":"Shah","year":"2017","journal-title":"Drugs Context"},{"key":"10.1016\/j.blre.2019.100594_bb0210","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.24668","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II eclipse study","volume":"92","author":"Taher","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12955-018-1041-5","article-title":"Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias","volume":"16","author":"Taher","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.blre.2019.100594_bb0220","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.12987","article-title":"Deferasirox for cardiac siderosis in \u03b2-thalassemia major: a multicenter, open label, prospective study","volume":"167","author":"Piga","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0225","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.25370","article-title":"Long-term improvement in cardiac magnetic resonance in beta-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function","volume":"94","author":"Casale","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0230","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/ajh.23844","article-title":"Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with \u03b2-thalassemia major","volume":"89","author":"Casale","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0235","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00277-016-2633-y","article-title":"Longitudinal changes of endocrine and bone disease in adults with \u03b2-thalassemia major receiving different iron chelators over 5 years","volume":"95","author":"Poggi","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0240","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1182\/blood-2016-05-712695","article-title":"Current growth patterns in children and adolescents with thalassemia major","volume":"128","author":"Origa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100594_bb0245","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3324\/haematol.2014.104463","article-title":"Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels","volume":"99","author":"Rossi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0250","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/j.gastro.2011.06.065","article-title":"Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years","volume":"141","author":"Deugnier","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2019.100594_bb0255","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25122","article-title":"Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent beta-thalassemia and other anemias","volume":"93","author":"Origa","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/435683","article-title":"The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients","volume":"2011","author":"Ceci","year":"2011","journal-title":"Anemia"},{"key":"10.1016\/j.blre.2019.100594_bb0265","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/10245332.2015.1101971","article-title":"The Italian multiregional thalassemia registry: centers characteristics, services, and patients' population","volume":"21","author":"Conte","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2019.100594_bb0270","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.12340","article-title":"Assessment and management of iron overload in \u03b2-thalassemia major patients during the 21st century: a real-life experience from the Italian webthal project","volume":"161","author":"Piga","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0275","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00277-017-2963-4","article-title":"Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000\u20132015","volume":"96","author":"Origa","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0280","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European society for blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.100594_bb0285","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/ajh.24898","article-title":"Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment","volume":"92","author":"Caocci","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0290","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood-2013-05-502658","article-title":"Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia","volume":"122","author":"La Nasa","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100594_bb0295","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcmd.2015.03.010","article-title":"Thalassemia major between liver and heart: where we are now?","volume":"55","author":"Dess\u00ec","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0300","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ejechocard\/jeq190","article-title":"Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study","volume":"12","author":"Derchi","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.blre.2019.100594_bb0305","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.15125","article-title":"Gender differences in the development of cardiac complications: a multicentre study in a large cohort of thalassaemia major patients to optimize the timing of cardiac follow-up","volume":"180","author":"Pepe","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0310","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3324\/haematol.2010.025510","article-title":"Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study","volume":"96","author":"Marsella","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0315","first-page":"1","article-title":"Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited","author":"Derchi","year":"2018","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.blre.2019.100594_bb0320","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.113.002124","article-title":"Prevalence and risk factors for pulmonary arterial hypertension in a large group of \u03b2-thalassemia patients using right heart catheterization: a webthal study","volume":"129","author":"Derchi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2019.100594_bb0325","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1196\/annals.1345.051","article-title":"Osteoporosis in \u03b2-thalassemia: clinical and genetic aspects","volume":"1054","author":"Origa","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2019.100594_bb0330","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/bjh.13009","article-title":"Hepatocellular carcinoma in thalassaemia: an update of the Italian registry","volume":"167","author":"Borgna-Pignatti","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0335","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/apt.14197","article-title":"Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection","volume":"46","author":"Mangia","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.blre.2019.100594_bb0340","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/ajh.24911","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies","volume":"92","author":"Origa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0345","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-010-1007-0","article-title":"Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major","volume":"89","author":"Baldini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0350","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00277-017-2959-0","article-title":"Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables","volume":"96","author":"Baldini","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0355","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","article-title":"Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study","volume":"158","author":"Forni","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0360","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00421-011-2072-3","article-title":"Relationship of low plasma klotho with poor grip strength in older community-dwelling adults: the Inchianti study","volume":"112","author":"Semba","year":"2012","journal-title":"Eur J Appl Physiol"},{"key":"10.1016\/j.blre.2019.100594_bb0365","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/03630269.2017.1403927","article-title":"Pseudoxanthoma elasticum-like in beta-thalassemia major, a matter of alpha-klotho and parathyroid hormone?","volume":"41","author":"Baldan","year":"2017","journal-title":"Hemoglobin"},{"key":"10.1016\/j.blre.2019.100594_bb0370","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00774-014-0584-8","article-title":"Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials","volume":"32","author":"Giusti","year":"2014","journal-title":"J Bone Miner Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100594_bb0375","first-page":"158","article-title":"Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the ferrara centre","volume":"6","author":"Gamberini","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.blre.2019.100594_bb0380","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2016.022","article-title":"Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions: a long-term retrospective study (40 years) in a tertiary care center in Italy","volume":"8","author":"De Sanctis","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0385","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1562-z","article-title":"Low-dose Synachten test with measurement of salivary cortisol in adult patients with beta-thalassemia major","volume":"60","author":"Ambrogio","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.blre.2019.100594_bb0390","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1002\/ajh.24726","article-title":"Adrenal insufficiency: an emerging challenge in thalassemia?","volume":"92","author":"Baldini","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0395","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-nutr-082117-051732","article-title":"Iron and cancer","volume":"38","author":"Torti","year":"2018","journal-title":"Annu Rev Nutr"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100594_bb0400","first-page":"314","article-title":"Papillary thyroid cancer in thalassaemia","volume":"8","author":"Govoni","year":"2011","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.blre.2019.100594_bb0405","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03630269.2011.588355","article-title":"Malignancies in beta-thalassemia patients: first description of two cases of thyroid cancer and review of the literature","volume":"35","author":"Poggi","year":"2011","journal-title":"Hemoglobin"},{"key":"10.1016\/j.blre.2019.100594_bb0410","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0531-5565(86)90044-6","article-title":"Anatomic and physiologic age changes in the kidney","volume":"21","author":"Lindeman","year":"1986","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.blre.2019.100594_bb0415","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/sj.ki.5002038","article-title":"Acute kidney injury following proton pump inhibitor therapy","volume":"71","author":"Brewster","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2019.100594_bb0420","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5414\/CN108966","article-title":"Acute kidney injury in allopurinol-induced dress syndrome: a case report of concurrent tubulointerstitial nephritis and kidney-limited necrotizing vasculitis","volume":"87","author":"Esposito","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.blre.2019.100594_bb0425","first-page":"R1542","article-title":"Hemodynamics and organ blood flow in fetal sheep subjected to chronic anemia","volume":"261","author":"Davis","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.blre.2019.100594_bb0430","first-page":"2","article-title":"Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease","volume":"17","author":"Lafferty","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0435","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1080\/10715760802459879","article-title":"Iron-deficiency anaemia enhances red blood cell oxidative stress","volume":"42","author":"Nagababu","year":"2008","journal-title":"Free Radic Res"},{"key":"10.1016\/j.blre.2019.100594_bb0440","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1681\/ASN.2005070757","article-title":"Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure","volume":"17","author":"Nangaku","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2019.100594_bb0445","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1523-1755.2004.00716.x","article-title":"Parenteral iron nephrotoxicity: potential mechanisms and consequences","volume":"66","author":"Zager","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2019.100594_bb0450","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1523-1755.2004.00638.x","article-title":"Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury","volume":"65","author":"Zager","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2019.100594_bb0455","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s004670000434","article-title":"Renal function in pediatric patients with beta-thalassemia major","volume":"15","author":"Aldudak","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.blre.2019.100594_bb0460","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000044904","article-title":"Renal function in adult beta-thalassemia\/Hb E disease","volume":"78","author":"Ong-ajyooth","year":"1998","journal-title":"Nephron"},{"key":"10.1016\/j.blre.2019.100594_bb0465","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s004670050453","article-title":"Renal tubular function in beta-thalassemia","volume":"12","author":"Sumboonnanonda","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.blre.2019.100594_bb0470","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00277-013-1833-y","article-title":"Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters","volume":"93","author":"Ricchi","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2019.100594_bb0475","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3109\/0886022X.2015.1007871","article-title":"Urinary early kidney injury molecules in children with beta-thalassemia major","volume":"37","author":"Sen","year":"2015","journal-title":"Ren Fail"},{"key":"10.1016\/j.blre.2019.100594_bb0480","first-page":"514","article-title":"Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis","volume":"77","author":"Cianciulli","year":"1992","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0485","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/ndt\/gfq224","article-title":"Acute renal failure and Fanconi syndrome due to deferasirox","volume":"25","author":"Grange","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.blre.2019.100594_bb0490","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.ajkd.2009.03.013","article-title":"Fanconi syndrome due to deferasirox","volume":"54","author":"Rafat","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0495","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100594_bb0500","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjh.13217","article-title":"Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent beta thalassaemia","volume":"168","author":"Piga","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0505","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.blre.2010.08.004","article-title":"Renal complications in transfusion-dependent beta thalassaemia","volume":"24","author":"Ponticelli","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100594_bb0510","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard.57.12.742","article-title":"Down regulation by iron of prostaglandin E2 production by human synovial fibroblasts","volume":"57","author":"Hisakawa","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2019.100594_bb0515","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ki.2008.145","article-title":"Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice","volume":"74","author":"Schnermann","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2019.100594_bb0520","author":"Casale"},{"key":"10.1016\/j.blre.2019.100594_bb0525","first-page":"7","article-title":"Pseudoxanthoma-elasticum-like syndrome and thalassemia: an update","volume":"15","author":"Fabbri","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.blre.2019.100594_bb0530","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ejh.12121","article-title":"Effect of splenectomy on iron balance in patients with beta-thalassemia major: a long-term follow-up","volume":"91","author":"Casale","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.100594_bb0535","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s11136-018-1911-7","article-title":"Quality of life in Sardinian patients with transfusion-dependent thalassemia: a cross-sectional study","volume":"27","author":"Floris","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.blre.2019.100594_bb0540","first-page":"231","article-title":"Changes in the quality of life of people with thalassemia major between 2001 and 2009","volume":"7","author":"Gollo","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2019.100594_bb0545","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100594_bb0550","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","article-title":"Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia","volume":"133","author":"Piga","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100594_bb0555","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/hum.2018.122","article-title":"Gene therapy for Hemoglobinopathies","volume":"29","author":"Cavazzana","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2019.100594_bb0560","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood-2019-01-895094","article-title":"Editing aberrant splice sites efficiently restores beta-globin expression in beta-thalassemia","volume":"133","author":"Xu","year":"2019","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:14Z","timestamp":1759436534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19300396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":112,"alternative-id":["S0268960X19300396"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100594","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of the aging beta-thalassemia transfusion-dependent population \u2013 The Italian experience","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100594"}}